A Non-interventional, Prospective Study With Benralizumab

Asthma, Bronchial Clinical Trial

— AIR POWER  

Official title:

A Non-interventional, Prospective Study With Benralizumab to Investigate Clinical Outcome Based on Standard of Care Medication in Real-life

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06422078
• Other study ID #: D3250R00124
• Status: Not yet recruiting
• Start date: June 30, 2024
• Est. completion date: June 30, 2026

Study information

• Verified date: May 2024
• Source: AstraZeneca
• Contact: AstraZeneca Clinical Study Information Center
• Phone: 1-877-240-9479
• Email: information.center[@]astrazeneca.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a prospective, non-interventional, single-arm, multicenter study to investigate asthma control, and health-related quality of life (HRQL), lung function and asthma medication intake in severe eosinophilic asthma patients treated with benralizumab in a real-life setting in Germany.

Description:

This is a prospective observational study to investigate the asthma control and health realted quality of life (HRQL) of benralizumab treated patients in routine clinical practice, their asthma medication intake, and their changes in asthma medication during the study, up to 52 weeks.

The asthma control will be analyzed by using the Asthma Control Test (ACT) and the Asthma Impairment and Risk Questionnaire (AIRQ®) at different timepoints during the study period either collected by the investigator or self-reported by the patient. In addition, health realted quality of life will be assessed at baseline and routine follow-up visits using the mini Asthma Quality of Life Questionnaire (miniAQLQ) which is collected by the investigator. To investigate the medication intake and assess the changes in asthma medication, the patients will record their weekly medication intake in a paper-based or an electronic medication diary throughout the study.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 300
• Est. completion date: June 30, 2026
• Est. primary completion date: June 30, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 120 Years

Eligibility

Inclusion Criteria:

• Male or female patients aged 18 years or older

• Confirmed diagnosis of severe eosinophilic asthma (defined according to the European Respiratory Society and American Thoracic Society and local German guidelines) treated with high-dose inhaled corticosteroids (ICS) plus long-acting beta agonists (LABA)

• Prescribed treatment with benralizumab according to label and local market reimbursement criteria

• Benralizumab treatment was not part of the study decision and treatment decision was met prior and independently of the study

• Patients must be able and willing to read and comprehend written instructions

• After full explanation, patients must have signed an informed consent form (ICF) indicating that they understand the purpose of, and the procedures required for the study and are willing to participate in the study

• Patients must be willing to report asthma patient-reported outcomes (PROs) every 4 weeks and medication intake weekly

Exclusion Criteria:

• Patients who participate in an observational trial that might, in the investigators' opinion, influence the assessment for current study; or participated in a randomized clinical trial in the last 3 months

• History of anaphylaxis to any biologic therapy

• Prior treatment with any asthma biologic therapy within the last 6 months

• Concurrent biologic therapy

• Helminth parasitic infection diagnosed within 24 weeks prior to the date informed consent was obtained that had not been treated with, or had failed to respond to standard of care (SOC) therapy

• Any other pulmonary disease than asthma that, in the investigator's point of view, would have an impact on the interpretation of results

• An acute or chronic condition that, in the investigator's point of view, would limit the patient's ability to complete questionnaires or participate in this study or impact the interpretations of results

• Current or history of malignancy within 5 years before the enrolment date with the following exceptions:

• In-situ carcinoma of the cervix where curative therapy has been completed and patients are in remission for at least 12 months prior to enrolment date

• Basal cell or superficial squamous skin cancer

• Pregnancy or lactation period (status to be proactively asked by the investigator)

• Any condition, that, in the opinion of the investigator, could jeopardize the safety of the patient

Related Conditions & MeSH terms

• Asthma
• Asthma, Bronchial

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
AstraZeneca

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Asthma Control Test (ACT) total score in patients from baseline to week 12, 24 and 52 after first benralizumab dose	To assess asthma control in patients initiating treatment with benralizumab over time.; The ACT includes 5 questions. The score can range from 5 (worst control) to 25 (best control). Scores between 20 and 25 indicate well-controlled asthma, and scores lower than 20 indicate patients with not-well controlled asthma.	From baseline to week 12, 24 and 52
Primary	Proportion of responders at baseline, week 12, 24 and 52 after first benralizumab dose, using ACT	To assess asthma control in patients initiating treatment with benralizumab. Responders are defined as patients with well-controlled asthma (ACT score =20).	At baseline, week 12, 24 and 52
Primary	Change in daily doses of prescribed inhaled corticosteroids (ICS) intake from baseline to week 12, 24 and 52 after first benralizumab dose	To assess prescribed daily ICS dose of benralizumab treated patients over time. Doses of medication will be converted to equivalents to be able to make comparisons.	From baseline to week 12, 24 and 52
Primary	Change in daily doses of patient-reported inhaled corticosteroids (ICS) intake from baseline to week 12, 24 and 52 after first benralizumab dose	To assess patient-reported daily ICS dose of benralizumab treated patients over time. Doses of medication will be converted to equivalents to be able to make comparisons.	From baseline to week 12, 24 and 52
Primary	Reduction (in percentage) in prescribed daily ICS dose intake from baseline to week 52 after first benralizumab dose	To assess prescribed daily ICS dose of benralizumab treated patients with ICS dose reduction.	From baseline to week 52
Primary	Reduction (in percentage) in patient-reported daily ICS dose intake from baseline to week 52 after first benralizumab dose	To assess patient-reported daily ICS dose of benralizumab treated patients with ICS dose reduction.	From baseline to week 52
Secondary	Proportion of patients meeting any individual criteria for remission at baseline, week 24 and 52 after first benralizumab dose	To describe the proportion of patients who meet any individual criteria for remission.; Criteria for remission are defined as no exacerbation, no prescribed use of oral corticosteroids (OCS) for asthma, ACT score =20, and stable lung function).	At baseline, week 24 and 52
Secondary	Proportion of patients fulfilling all the criteria for remission at baseline, week 24 and 52 after first benralizumab dose	To describe the proportion of patients who meet all criteria for remission after initiation of benralizumab treatment.	At baseline, week 24 and 52
Secondary	Total Asthma Impairment and Risk Questionnaire® (AIRQ®) score reduction from baseline to every 4 weeks after first benralizumab dose	To assess diaries reported asthma control in patients initiating treatment with benralizumab using the AIRQ® score.; The AIRQ® includes 10 questions (7 assessing symptom impairment and 3 assessing risk) concerning patient medication use, asthma symptoms, medical visits, and tests. The AIRQ® can predict the risk for exacerbations and assess the quality of life of asthma patients.; AIRQ® score: well-controlled (0-1 points), not well-controlled (2-4 points) and very poorly controlled (=5 points) asthma	From baseline to week 52
Secondary	Total ACT score reduction from baseline to every 4 weeks after first benralizumab dose	To assess diaries reported asthma control in patients initiating treatment with benralizumab using the ACT score.	From baseline to week 52
Secondary	Change in total Mini Asthma Quality of Life Questionnaire (miniAQLQ) score from baseline to week 12, 24, and 52 after first benralizumab dose	To describe patient-reported health-related quality of life (HRQL) in patients initiating treatment with benralizumab using the miniAQLQ.; The miniAQLQ is composed of 15 questions covering 4 different domains, namely symptoms, activities, emotions, and environment experienced during the previous 2 weeks. The score in each item can vary from 1 to 7, with a higher score indicating better quality of life (QoL). The mean score is calculated as the total score divided by the number of items, and the domain scores are calculated as the total score divided by the number of items for respective domain. A change in score of =0.5 can be considered clinically important	From baseline to week 12, 24 and 52
Secondary	Change in daily doses of prescribed relevant background medication from baseline to week 12, 24 and 52 after first benralizumab dose	To describe the proportion of patients regarding prescribed standard-of-care (SOC) asthma medication dose change in patients initiating treatment with benralizumab.	From baseline to week 12, 24 and 52
Secondary	Proportion of patients with increased daily dose of relevant background medication from baseline to week 12, 24 and 52 after first benralizumab dose	To describe the proportion of patients regarding prescribed increased SOC asthma medication dose in patients initiating treatment with benralizumab.	From baseline to week 12, 24 and 52
Secondary	Proportion of patients with decreased daily dose of relevant background medication from baseline to week 12, 24 and 52 after first benralizumab dose	To describe the proportion of patients regarding prescribed decreased SOC asthma medication dose in patients initiating treatment with benralizumab.	From baseline to week 12, 24 and 52
Secondary	Proportion of patients with equal daily dose of relevant background medication from baseline to week 12, 24 and 52 after first benralizumab dose	To describe the proportion of patients regarding prescribed equal SOC asthma medication dose in patients initiating treatment with benralizumab.	From baseline to week 12, 24 and 52
Secondary	Annualized exacerbation rate assessed at baseline, week 12, 24 and 52 after first benralizumab dose	To assess the annualized asthma exacerbation rate in patients initiating treatment with benralizumab.	From baseline to week 12, 24 and 52
Secondary	Proportion of patients without exacerbations at baseline, week 12, 24 and 52 after first benralizumab dose	To describe the proportion of patients without asthma exacerbations in patients initiating treatment with benralizumab.	From baseline to week 12, 24 and 52
Secondary	Level of lung function parameters - forced expiratory volume in the first second (FEV1) and forced vital capacity (FVC) at baseline, week 12, 24 and 52 after first benralizumab dose	To describe the FEV1 and FVC levels in patients initiating treatment with benralizumab.; From FEV1 and FVC the Tiffenau-Index will be calculated as follows: FEV1/FVC	At baseline, week 12, 24 and 52
Secondary	Level of lung function parameters - residual volume (RV) at baseline, week 12, 24 and 52 after first benralizumab dose	To describe the level of RV in patients initiating treatment with benralizumab.	At baseline, week 12, 24 and 52
Secondary	Level of lung function parameters - total lung capacity (TLC) at baseline, week 12, 24 and 52 after first benralizumab dose	To describe the level of TLC in patients initiating treatment with benralizumab.	At baseline, week 12, 24 and 52
Secondary	Level of lung function parameters - total specific airway resistance (sRtot) at baseline, week 12, 24 and 52 after first benralizumab dose	To describe the level of sRtot in patients initiating treatment with benralizumab.	At baseline, week 12, 24 and 52
Secondary	Level of diffusing capacity of the lungs for carbon monoxide (DLCO) at baseline, week 12, 24 and 52 after first benralizumab dose	To describe the level of DLCO in patients initiating treatment with benralizumab.	At baseline, week 12, 24 and 52
Secondary	Level of biomarkers - eosinophils at baseline, week 12, 24 and 52 after first benralizumab dose	To describe the level of eosinophils in patients initiating treatment with benralizumab.; Measured in cells per microliter.	At baseline, week 12, 24 and 52
Secondary	Level of biomarkers - total immunglobulin E (IgE) at baseline, week 12, 24 and 52 after first benralizumab dose	To describe the level of total IgE in patients initiating treatment with benralizumab.; Total IgE, measured in international units per milliliter (IU/ml).	At baseline, week 12, 24 and 52
Secondary	Level of biomarkers - fractional exhaled nitric oxide (FeNO) at baseline, week 12, 24 and 52 after first benralizumab dose	To describe the level of FeNO in patients initiating treatment with benralizumab.; Measured in parts per billion (ppb).	At baseline, week 12, 24 and 52